Concepedia

Publication | Closed Access

Plasma <scp>HMGB</scp>‐1 after the initial dose of epirubicin/docetaxel in cancer

DOI

31

Citations

12

References

2013

Year

Tobias Arnold, Anna Michlmayr, Suzann Baumann, Christopher Burghuber, Ursula Pluschnig, Rupert Bartsch, Guenther G. Steger, Michael Gnant, Michael Bergmann, Thomas Bachleitner‐Hofmann,
European Journal of Clinical Investigation

Abstract

Our data suggest that early dynamic changes of plasma HMGB1 could be a promising biomarker to predict the final response to NCT in breast cancer patients.

References

YearCitations

Page 1